We are international



  1. Comparison of 200 mg m2 melphalan Moreau 2002 BLOOD
  2. Single versus Double Autologous Stem Cell Transplant for MM, Attal 2003 NEJM
  3. High Dose Chemotherapy with hematopoietic stem-cell rescue in MM Child, 2003 NEJM
  4. IMWG Stem Cell Collection Giralt 2009 Leukemia
  5. Complete Remission in multiple myeloma examined as time-dependent variable Hoering 2009 BLOOD
  6. Editorial: Stem Cell collection before high dose therapy for mm. Time has come to raise the standards. Mohty 2009 Leukemia
  7. Stem Cell Transplant in myeloma. Impact of response failure with THAL or LEN Induction. Gertz 2010 BLOOD
  8. Melphalan 200 mg.m2 versus melphalan 100 mg.mm.m2 in newly diagnosed myeloma patients Palumbo. 2010 BLOOD
  9. Bortezomib, Thalidomide and Dexamethasone compared with thal and dex as induction. Cavo 2010 LANCET
  10. Consensus Statement regarding the current status of ALLO SCT for MM. Lokhorst 2010 Leukemia
  11. Trends in allo stem cell transplantation for mm – a CIBMTR analysis Kumar. 2011 BLOOD
  12. Long-Term Follow-Up of a comparison of nonmyeloablative allografting. Giaccone, 2011 BLOOD
  13. Lenalidomide maintenance after nonmyeloablative allo STC. Kneppers 2011 BLOOD
  14. Long-term prognostic significance of response in multiple myeloma after STC. Martinez-Lopez. 2011 BLOOD
  15. Bortezomib plus dexamethasone versus reduced-dose bortezomib, THAL plus DEX. Moreau 2011 BLOOD
  16. Have drug combinations supplanted stem cell transplantation in myeloma? Palumbo and Cavallo. BLOOD 2012; 120: 4692-4698.


 related articles